Kymera
degrader investigational drug is superior to small molecule inhibitors | Kymera
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
53 of 60
Similar slides by Kymera
See diffirences between slides (animation)
Investor Presentation
December 2023
is superior to small molecule inhibitors | Kymera
Investor Presentation
November 2023
is superior to small molecule inhibitors | Kymera
Investor Presentation
June 2023
degrader investigational drug is superior to small molecule inhibitors | Kymera
Investor Day
December 2021
degrader development candidate is superior to small molecule inhibitors | Kymera
Related slides by other companies
SentiBio
SPAC
October 2021
or car cells significantly suppressed tumor growth reduced tumor burden and improved survival cancer bice model | SentiBio
Absci
Investor Conference
January 2024
platform designed advanced leads with high affinity and superior potency data highlights | Absci
Apexigen
SPAC
March 2022
potent anti tumor activity in preclinical models | Apexigen
23andMe
Investor Presentation
January 2024
| 23andMe
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
June 2023
Results
December 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io